Domov › CHOPN › Texas

Klinické štúdie CHOPN v štáte Texas

25 štúdií pre CHOPN hľadá účastníkov v zariadeniach v štáte Texas.

Mestá v štáte Texas

Oficiálny text štúdie (anglicky)

A Study Evaluating the Efficacy of Budesonide, Glycopyrronium and Formoterol Fumarate Metered Dosed Inhaler on Cardiopulmonary Outcomes in Chronic Obstructive Pulmonary Disease

Research Site, Abilene
Research Site, Brownsville
Research Site, Dallas
a 12 ďalších

Prebieha náborFáza 3

Vek 40 až 80 · Všetky pohlavia · Aktualizované 2. 10. 2026 · NCT06283966

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype

Solace Clinical Research- Site Number : 8400087, Austin
IntraCare- Site Number : 8400034, Dallas
Premier Pulmonary Critical Care and Sleep- Site Number : 8400111, Denison
a 7 ďalších

Prebieha náborFáza 3

Vek 40 až 80 · Všetky pohlavia · Aktualizované 1. 10. 2026 · NCT07190222

To Evaluate the Effect of EXPD-101/FXS7553 Compared With Placebo in Patients With COPD Over 52 Weeks of Treatment

Horizon Clinical Research Group., Cypress
Metroplex Pulmonary and Sleep Center, McKinney
DM Clinical Research- Tomball, Tomball

Prebieha náborFáza 2

Vek 40 až 85 · Všetky pohlavia · Aktualizované 30. 9. 2026 · NCT07684820

A Study of 24 to 52 Weeks Treatment to Evaluate The Efficacy And Safety of Galvokimig in Study Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD) With Chronic Bronchitis

Copd01 50001, Boerne

Prebieha náborFáza 2

Vek 40 až 80 · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT07725939

A Study of Brenipatide (LY3537031) in Adult Participants With Moderate-to-Severe Chronic Obstructive Pulmonary Disease (COPD)

Premier Pulmonary Critical Care and Sleep, Denison
Baylor College of Medicine Medical Center, Houston
Prime Clinical Research - Lewisville, Lewisville

Prebieha náborFáza 2

Vek 40 až 75 · Všetky pohlavia · Aktualizované 25. 9. 2026 · NCT07759245

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype

Wellness Clinical Research - Allen- Site Number : 8400085, Allen
REX Clinical Trials - Beaumont- Site Number : 8400014, Beaumont
Novel Research - Bellaire- Site Number : 8400116, Bellaire
a 17 ďalších

Prebieha náborFáza 3

Vek 40 až 80 · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07190209

A Study to Investigate Airway Inflammation With Dupilumab Subcutaneously in Participants Aged ≥40 to ≤85 Years With Chronic Obstructive Pulmonary Disease.

REX Clinical Trials - Beaumont- Site Number : 8400011, Beaumont

Prebieha náborFáza 4

Vek 40 až 85 · Všetky pohlavia · Aktualizované 22. 9. 2026 · NCT07053423

An Evaluation of the AeriSeal System for CONVERTing Collateral Ventilation Status in Patients With Severe Emphysema

University of Texas Southwestern, Dallas

Prebieha nábor

Vek 40 až 80 · Všetky pohlavia · Aktualizované 17. 9. 2026 · NCT06035120

A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)

WB Contracted Clinical Research Site, McKinney
WB Contracted Clinical Research Site, Waxahachie

Prebieha náborFáza 2

Vek 40 až 80 · Všetky pohlavia · Aktualizované 15. 9. 2026 · NCT07646587

A Study to Investigate the Effect of AZD6793 in Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease

Research Site, Boerne
Research Site, Dallas
Research Site, Denison
a 5 ďalších

Prebieha náborFáza 2

Vek 40 a viac · Všetky pohlavia · Aktualizované 9. 9. 2026 · NCT07082738

Clinical Trial of Omalizumab for Allergen Sensitized and Exposed Individuals With COPD

Baylor College of Medicine, Houston

Prebieha náborFáza 2

Vek 40 a viac · Všetky pohlavia · Aktualizované 4. 9. 2026 · NCT07059091

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00007)

Research Site, Boerne
Research Site, El Paso
Research Site, Houston
a 6 ďalších

Prebieha náborFáza 3

Vek 40 až 80 · Všetky pohlavia · Aktualizované 3. 9. 2026 · NCT06878261

A Study to Investigate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe COPD (D5241C00006)

Research Site, Dallas
Research Site, Forney
Research Site, Fort Worth
a 5 ďalších

Prebieha náborFáza 3

Vek 40 až 80 · Všetky pohlavia · Aktualizované 3. 9. 2026 · NCT06883305

The Study of Chronic Obstructive Pulmonary Disease (COPD) Participants Treated With Dupilumab (STRIDE) Registry

The Lung & Sleep Institute of North Texas, North Richland Hills

Prebieha náborObservačná štúdia

Vek 40 a viac · Všetky pohlavia · Aktualizované 1. 9. 2026 · NCT07612878

A Study to Learn About the Study Medicine Called PF-07275315 in People With Moderate to Severe Chronic Obstructive Pulmonary Disease

South Texas Medical Research Institute, Inc., DBA TTS Research, Boerne
Ten20 Clinical Research, Carrollton
Horizon Clinical Research Group, Cypress
a 4 ďalších

Prebieha náborFáza 2/3

Vek 35 až 80 · Všetky pohlavia · Aktualizované 31. 8. 2026 · NCT07363694

A Non-inferiority Pharmacokinetic and Safety/Tolerability Study of Two Different Doses of Weekly SC Alpha1-PI 15% Compared With Corresponding Standard IV Alpha1-PI in Participants With Alpha1-Antitrypsin Deficiency (AATD)

GC2501 Study Site 109, Dallas

Prebieha náborFáza 3

Vek 18 až 80 · Všetky pohlavia · Aktualizované 11. 8. 2026 · NCT07555483

STRIVE Post-Market Registry Study

Baylor Scott & White Research Institute, Dallas
University of Texas Southwestern, Dallas
University of Texas Health Science Center at Houston, Houston

Prebieha náborObservačná štúdia

Vek 18 a viac · Všetky pohlavia · Aktualizované 3. 8. 2026 · NCT04302272

eValuating the Efficacy and Safety of InitiatinG depemokImab earLy therApy iN Chronic Obstructive Pulmonary Disorder (COPD) With Type 2 Inflammation

GSK Investigational Site, Dallas
GSK Investigational Site, DeSoto
GSK Investigational Site, Greenville
a 6 ďalších

Prebieha náborFáza 3

Vek 40 až 75 · Všetky pohlavia · Aktualizované 28. 7. 2026 · NCT07177339

Collection of Blood From Healthy Patients, Patients With Benign Disease and Patients With Cancer

Liver Center of Texas, Dallas
Methodist Hospital, Richardson

Prebieha náborObservačná štúdia

Vek 18 a viac · Všetky pohlavia · Aktualizované 10. 7. 2026 · NCT05181826

Bronchoscopic RElease of Air Trapped in Hyperinflated Emphysematous Lung - Study 3

Houston Methodist/Primary Critical Care, Houston

Prebieha nábor

Vek 40 až 84 · Všetky pohlavia · Aktualizované 24. 4. 2026 · NCT06891755

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA-2)

GSK Investigational Site, Austin
GSK Investigational Site, Dallas
GSK Investigational Site, El Paso
a 5 ďalších

Prebieha náborFáza 3

Vek 40 až 80 · Všetky pohlavia · Aktualizované 9. 4. 2026 · NCT06961214

Depemokimab as an Extended treatmeNt Duration Biologic in Adults With Chronic Obstructive Pulmonary Disease (COPD) and Type 2 Inflammation (ENDURA -1)

GSK Investigational Site, Corsicana

Prebieha náborFáza 3

Vek 40 až 80 · Všetky pohlavia · Aktualizované 8. 10. 2025 · NCT06959095

Interprofessional Pharmacogenomics (IPGx) Registry and Repository

Texas A&M Family Care, Bryan

Prebieha náborObservačná štúdia

Vek 18 a viac · Všetky pohlavia · Aktualizované 12. 9. 2025 · NCT06726590

Clinical Validation of Freenome Multiomics Blood Test for Lung Cancer Screening

Horizon Clinical Research Group, Houston
CHRISTUS Trinity Mother Frances Health System, Tyler

Prebieha náborObservačná štúdia

Vek 50 a viac · Všetky pohlavia · Aktualizované 5. 8. 2025 · NCT06122077

myAirvo 3 (High Flow Nasal Therapy; HFNT) for COPD Patients in the Home

Respire Research Institute, Houston

Prebieha nábor

Vek 30 a viac · Všetky pohlavia · Aktualizované 6. 2. 2025 · NCT05204888

Z ClinicalTrials.gov, dáta načítané 4. 10. 2026. Každá štúdia má vlastné kritériá oprávnenosti; tím štúdie rozhoduje o účasti.